T
rue to the publication of diverse issues that comprise and challenge the field of allergy and immunology, the allergist/immunologists, and the patients we serve, this issue of the Proceedings features a Janus spectrum of articles that bridge diverse conditions, which range from chronic urticarial, food allergy, asthma, allergic rhinoconjunctivitis to immunodeficiency and drug allergy, all of which present with a dichotomy of disease expression that challenges the expertise of the allergist/immunologist.
Nowhere is this polarity of disease expression better illustrated than by the burden of illness related to chronic urticaria, which spans the life spectrum from infancy to the elderly. Filling a void for more information regarding chronic urticaria in the pediatric population, Azkur et al. 1 evaluated the clinical features, possible causes, associated findings, and laboratory results of different subtypes of chronic urticaria in 222 children. When treatment options, e.g., antihistamines, for patients with chronic urticaria are ineffectual, oral corticosteroids are commonly used. However, the risks associated with oral corticosteroid therapy among patients with chronic urticarial have not been fully elucidated. To this end Ledford et al. 2 analyzed a commercial claims data base of Ͼ12,000 patients with chronic urticaria to assess the relationship between oral corticosteroid use and the associated risk of developing adverse effects to oral corticosteroids and the associated health care costs. In this issue of the Proceedings, they reported that patients with chronic urticaria who were treated with oral corticosteroid have an increased risk of oral corticosteroid-related adverse effects and higher total health care costs. 2 Another cutaneous condition that requires the expertise of the allergy/immunology specialist is hereditary angioedema. One of the frequently used treatment options is C1 inhibitor, which is currently available only for the intravenous route of administration. 3 A subcutaneous formulation of C1 inhibitor may provide a preferred mode of administration for some patients; and, in this issue of the Proceedings, Riedl et al. 4 report their results of a randomized, double-blind, dose-ranging, crossover study of subcutaneous, plasma-derived C1 inhibitor with the dispersing agent recombinant human hyaluronidase in 47 patients with the diagnosis of hereditary angioedema.
A disorder often considered in the differential diagnosis of urticaria and angioedema is food allergy. The diagnosis of this condition may ultimately require confirmatory oral food challenge, a test considered to be the criterion standard for diagnosing food allergy. 5 In this issue of the Proceedings, Wang 6 provides a lucid review of the utility of component diagnostic testing in guiding oral food challenges to milk and egg. Advancements in diagnostic testing for food allergy have been propelled by its rising prevalence, 7 which is frequently attributed to the hygiene hypothesis. To explore this hypothesis further, a study of 1359 children was conducted by Gupta et al. 8 who report the associations between childhood food allergy and asthma with hygiene factors, such as the number of siblings, antibiotic usage, infection history, pet exposure, childcare exposure, and maternal-child factors.
How hygiene factors affect the prevalence and pathogenesis of asthma is yet another area of ongoing investigation. The pathogenesis of allergic asthma is primarily characterized by a Th2 cell abnormality in the IgE pathway, which indicates a possible role for follicular T-helper (Tfh) cells in the generation of excessive IgE accumulation. Gong et al. 9 investigated circulating Tfh-cells subset distribution in patients with asthma to assess the relationship between Tfh-cells subset distribution and serum IgE level. They report an altered circulating Tfh-cells subset distribution, and their findings indicated that this cell subset may play an important role in the pathogenesis of asthma.
The pathogenesis of asthma not only involves altered immune function but also an altered environmental response, which is reflected by seasonal trends in asthma exacerbations. To this end, Wisniewski et al. 10 compared seasonal trends in asthma exacerbations among school-age children who lived in different geographic locations within the United States. They report that seasonal peaks for asthma exacerbations varied among children who lived in geographic locations with different climates and that were not restricted to the beginning of the school year. The anticipated outcome of the study was that the use of local, geographic information to recognize seasonal changes in the frequency of asthma exacerbations, together with individual patient risk factors (e.g., allergic sensitizations), would enhance efforts to optimize the treatment of children with asthma during periods when they are most likely to experience an attack. Because of the importance of this article and its clinically useful implications, it was chosen for this issue's "For the Patient" section. This segment, found in the final pages of the print version of issue of the Proceedings and also available online, consists of a one-page article synopsis written in a readily comprehensible fashion to help patients better understand the content of the full article.
Although it is intuitive that children who have experienced severe asthma exacerbations are at higher risk for admission to a pediatric intensive care unit, little is known how their clinical course may be affected after intensive care unit hospitalization. Abu-Kishk et al. 11 prospectively evaluated the outcome of children after pediatric intensive care unit admission and reported a deficiency of regular follow-up and controller therapy in most patients after asthma hospitalization. They suggest that this increased morbidity might be prevented.
A common feature of pediatric asthma is exerciseinduced bronchospasm, an entity that affects 80% of children with asthma and that usually responds to pretreatment with albuterol. Individualizing therapy for more challenging cases of exercise-induced bronchospasm requires further investigation. To this end Stelmach et al. 12 report the results of a randomized, double-blind, placebo-controlled clinical trial to assess the relative effectiveness of ciclesonide 160 g treatment either alone or at a higher dose, or with a leukotriene receptor antagonist, or with a long-acting ␤2-agonist in children after exercise-induced asthma symptoms.
In addition to their use in COPD, long-acting muscarinic antagonists have recently been approved for the treatment of asthma. Tiotropium, a once-daily longacting anticholinergic bronchodilator, has shown efficacy and safety as an add-on to maintenance therapy in patients with symptomatic asthma. Hoshino et al. 13 aimed to assess the effect of tiotropium on airway geometry and airway inflammation in patients with asthma who were symptomatic despite treatment with inhaled corticosteroid plus a long-acting ␤2-agonist. They report that the addition of once-daily tiotropium to maintenance therapy improved airflow limitation and reduced airway wall thickness.
Despite the increasing number of therapeutic options available for the establishment of asthma control, some patients with more severe asthma still require maintenance therapy with oral corticosteroids. However, as addressed by Ledford et al., 2 in patients with chronic urticaria, because oral corticosteroid therapy can be associated with serious adverse effects, asthma management strategies aimed at steroid sparing are now an important area of investigation. To this end, Nguyen and Ulrik 14 performed a systematic literature review in accordance with the PRISMA guidelines. They report that, in adults with severe asthma, both biologic and non-biologic corticosteroid-sparing interventions have been shown to be effective in reducing systemic steroid exposure. Biologic agents are an emerging class of agents with oral corticosteroid-sparing potential for patients with severe asthma. Biomarkers are recognized as predictive indicators of therapeutic response to biologic agents. COPD is another chronic respiratory condition for which biomarkers may be useful to identify phenotypes, treatment response, and prognosis. In this issue of the Proceedings, Brightling 15 reviews how the use of biomarkers for multidimensional phenotyping provides important clinical insights that enable the clinician to move toward a precision medicine approach for COPD.
Transitioning from the lower to the upper airway, asthma and nasal obstructive syndromes, e.g., rhinitis, have been shown to be contributing risk factors for obstructive sleep apnea. Calais et al. 16 emphasized the anatomic homogeneity of the upper and lower airways in their review of inflammatory conditions that underlie and interrelate rhinitis, asthma, and obstructive sleep apnea.
Three articles in this issue of the Proceedings address immunodeficiency, an important area of expertise for the allergist/immunologist. In an article that addresses clinical pearls and pitfalls, Brooks and Ghaffari 17 provide a brief overview of idiopathic CD4 lymphocytopenia, a rare immunodeficiency of unknown etiology. One of the major challenges in primary immunodeficiency is making a timely diagnosis; unfortunately, the time from symptom onset to diagnosis for patients with primary immunodeficiency is often more than a decade. In addition to primary care clinicians, pulmonologists frequently encounter patients with recurrent respiratory infections. Orange et al. 18 report the result of a survey of lung specialists designed to identify opportunities to improve diagnosis and clinical management of patients with primary immunodeficiency among pulmonologists. Also, with regard to clinical management of this disease, Bonilla 19 extends our knowledge by reviewing intravenous and subcutaneous IgG replacement therapy.
Diagnostic testing for evaluation of hypersensitivity drug reactions is another area that requires the expertise of the allergist/immunologist. For many hypersensitivity drug reactions, skin testing has not been validated as a diagnostic tool. More specifically, for the evaluation of iodinated contrast media hypersensitivity reactions, little data are available regarding the value of skin testing. In a study designed to examine the predictive value of iodinated contrast media skin tests in patients with iodinated contrast-mediated hypersensitivity, Soyyigit et al. 20 report finding low sen-sitivity but a high negative predictive value of skin testing. In summary, the collection of articles found within the pages of this issue of the Proceedings provides further insight into important allergic, cutaneous, and respiratory disorders that afflict patients whom the allergist-immunologist serve. These articles highlight how both the beneficial and adverse effects of therapy continue to challenge the allergist/immunologist in decisionmaking and therapy. In keeping with the overall mission of this issue of the Proceedings, which is to distribute timely information regarding advancements in the knowledge and practice of allergy, asthma, and immunology to clinicians entrusted with the care of patients, it is our hope that the articles found within this issue will help foster enhanced patient management and outcomes. On behalf of the editorial board, we hope you enjoy the diversity of literature offered in this issue of the Proceedings.
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